Tearlab Corp (TEAR): Anthony E Altig , director of Tearlab Corp purchased 33,334 shares on May 9, 2016. The Insider buying transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.00 per share for a total value of $0.00 , the company said in a SEC Form 4 Filing.
Shares of TearLab Corp (TEAR) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.04 points or -5.19% at $0.73 with 95,155 shares getting traded. Post opening the session at $0.74, the shares hit an intraday low of $0.73 and an intraday high of $0.8184 and the price vacillated in this range throughout the day. The company has a market cap of $25 M and the number of outstanding shares has been calculated to be 3,38,28,647 shares. The 52-week high of TearLab Corp is $3.0299 and the 52-week low is $0.5995.
Company has been under the radar of several Street Analysts.TearLab Corp is Upgraded by Feltl & Co. to Strong Buy. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 5, 2016.
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company’s wholly owned subsidiary TearLab Research Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries metabolites (glucose) genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable the TearLab Pen and the TearLab Reader.